/ARVN
ARVN Stock - Arvinas, Inc.
Healthcare|BiotechnologyNASDAQ
$11.68+3.55%
+$0.40 (+3.55%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.93
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).81
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.22
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+15.6%upside
Target: $13.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ARVN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.56 – $11.80
TARGET (TP)$13.50
STOP LOSS$10.75
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.45
52W High$21.00
52W Low$5.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $263.40M | $78.50M | $131.40M | $53.60M | $25.90M |
| Gross Profit | $263.40M | $78.50M | $131.40M | $53.60M | $25.90M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-250,200,000 | $-401,500,000 | $-263,200,000 | $-188,400,000 | $-120,800,000 |
| Net Income | $-198,900,000 | $-367,300,000 | $-282,500,000 | $-191,000,000 | $-119,300,000 |
| Net Margin | -75.5% | -467.9% | -215.0% | -356.3% | -460.6% |
| EPS | $-2.77 | $-6.62 | $-5.31 | $-3.82 | $-3.02 |
Company Overview
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
38%
Hold / Neutral
12
57%
Sell / Underperform
1
5%
Analyst Consensus🔴 Bearish
8 Bullish13 Neutral/Bearish
Price Targets
$45
Average Target
↑ 285.3% Upside
Now
$6
Low
$45
Average
$104
High
Based on 22 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 15th 2025 | Goldman | Downgrade | Sell | $6 |
| September 24th 2025 | BofA Securities | Downgrade | Neutral | $10 |
| September 17th 2025 | Barclays | Resumed | Overweight | $16 |
| June 2nd 2025 | Leerink Partners | Downgrade | Market Perform | $9 |
| May 5th 2025 | Truist | Downgrade | Hold | $11 |
| May 2nd 2025 | TD Cowen | Downgrade | Hold | - |
| May 2nd 2025 | Jefferies | Downgrade | Hold | $10 |
| March 13th 2025 | Goldman | Downgrade | Neutral | $15← $70 |
| March 12th 2025 | Wedbush | Downgrade | Neutral | $12← $57 |
| March 11th 2025 | Oppenheimer | Downgrade | Perform | - |
| December 10th 2024 | BTIG Research | Initiation | Buy | $69 |
| November 18th 2024 | Stephens | Initiation | Overweight | $55 |
| February 28th 2024 | Oppenheimer | Reiterated | Outperform | $80← $95 |
| February 14th 2024 | Citigroup | Downgrade | Neutral | $55← $36 |
| February 1st 2024 | Goldman | Initiation | Buy | $70 |
Earnings History & Surprises
ARVNBeat Rate
50%
Last 18 quarters
Avg Surprise
+1.3%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$-0.48
Q4 2025
EPS Surprise History
Q1 24
-90.2%
$-2.53vs$-1.33
Q2 24
+34.5%
$-0.97vs$-1.48
Q3 24
+31.9%
$-0.49vs$-0.72
Q4 24
+22.7%
$-0.68vs$-0.88
Q1 25
+41.1%
$-0.63vs$-1.07
Q2 25
+232.6%
$1.14vs$-0.86
Q3 25
+3.4%
$-0.84vs$-0.87
Q4 25
+36.0%
$-0.48vs$-0.75
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 10, 2026 | $-0.55 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.75 | $-0.48 | +36.0% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.87 | $-0.84 | +3.4% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-0.86 | $1.14 | +232.6% | ✓ BEAT |
Q1 2025 | Feb 11, 2025 | $-1.07 | $-0.63 | +41.1% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $-0.88 | $-0.68 | +22.7% | ✓ BEAT |
Q3 2024 | Jul 30, 2024 | $-0.72 | $-0.49 | +31.9% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-1.48 | $-0.97 | +34.5% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-1.33 | $-2.53 | -90.2% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-1.52 | $-1.18 | +22.4% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-1.67 | $-1.25 | +25.1% | ✓ BEAT |
Q2 2023 | May 5, 2023 | $-1.46 | $-1.54 | -5.5% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-1.04 | $-1.56 | -50.0% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.98 | $-1.24 | -26.5% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-1.02 | $-1.32 | -29.4% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.85 | $-1.20 | -41.2% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.78 | $-1.00 | -28.2% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $2.85 | $-0.94 | -133.0% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.84 | $-1.03 | -22.6% | ✗ MISS |
Latest News
Barclays Maintains Overweight on Arvinas, Raises Price Target to $18
📈 PositiveBenzinga•Dec 17, 2025, 05:34 PM•Also:
Reported Saturday, Arvinas Reports ARV-393 Plus Glofitamab Delivers Significantly Enhanced Tumor Growth Inhibition And Increased Tumor Regression Versus Either Agent Alone
📈 PositiveBenzinga•Dec 8, 2025, 09:25 AM
Arvinas And Pfizer's Vepdegestrant Featured In Multiple Abstracts Accepted For SABCS 2025, Highlighting Novel PROTAC ER Degrader In ER+/HER2- Breast Cancer
📈 PositiveBenzinga•Nov 24, 2025, 12:09 PM•Also:
Stephens & Co. Maintains Overweight on Arvinas, Raises Price Target to $15
📈 PositiveBenzinga•Nov 10, 2025, 02:13 PM
Wells Fargo Maintains Overweight on Arvinas, Lowers Price Target to $15
➖ NeutralBenzinga•Nov 6, 2025, 03:41 PM
Barclays Maintains Overweight on Arvinas, Raises Price Target to $16
📈 PositiveBenzinga•Nov 6, 2025, 02:27 PM•Also:
Arvinas Q3 EPS $(0.48) Beats $(0.81) Estimate, Sales $41.900M Beat $23.600M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 12:06 PM
Arvinas To Present Preclinical Data For Its PROTAC BCL6 Degrader, ARV-393, In Combination With Glofitamab At 2025 American Society Of Hematology Annual Meeting
➖ NeutralBenzinga•Nov 3, 2025, 09:02 PM
BTIG Maintains Buy on Arvinas, Raises Price Target to $14
📈 PositiveBenzinga•Oct 30, 2025, 11:36 AM
Arvinas Announces Preclinical Data For ARV-806 Showing Robust, Differentiated Activity In Models of KRAS G12D-Mutated Cancer, At 2025 AACR-NCI-EORTC International Conference
📈 PositiveBenzinga•Oct 24, 2025, 08:02 PM
Arvinas To Present Preclinical Data For ARV-806 At 2025 At AACR-NCI-EORTC International Conference In Boston
➖ NeutralBenzinga•Oct 22, 2025, 08:03 PM
Arvinas Reports Vepdegestrant Maintained Quality Of Life And Delayed Symptom Worsening In ESR1-Mutated ER+/HER2- Advanced Breast Cancer Patients
📈 PositiveBenzinga•Oct 20, 2025, 08:36 AM
Goldman Sachs Downgrades Arvinas to Sell, Lowers Price Target to $6
📉 NegativeBenzinga•Oct 15, 2025, 11:24 AM
Arvinas And Pfizer To Highlight New Vepdegestrant Data For ESR1-Mutated Advanced Breast Cancer At ESMO 2025
📈 PositiveBenzinga•Oct 13, 2025, 11:08 AM•Also:
Reported Sunday, Arvinas Unveils Late-Breaking Phase 1 Data For ARV-102 Showing 90% LRRK2 Reduction And Modulation Of Neuroinflammatory Pathways
📈 PositiveBenzinga•Oct 6, 2025, 06:29 AM
Arvinas To Present ARV-102 Data At 2025 International Congress of Parkinson's Disease and Movement Disorders Oct. 7 And 8
➖ NeutralBenzinga•Oct 1, 2025, 11:03 AM
BTIG Maintains Buy on Arvinas, Lowers Price Target to $10
📈 PositiveBenzinga•Sep 18, 2025, 02:08 PM
Stephens & Co. Maintains Overweight on Arvinas, Lowers Price Target to $14
➖ NeutralBenzinga•Sep 18, 2025, 12:03 PM
Arvinas To Reduce Workforce By 15%; Most Significant Reductions Being Roles Related To Vepdegestrant Commercialization; Expects $4.5M Costs For Workforce Reduction
📉 NegativeBenzinga•Sep 17, 2025, 08:53 PM
Arvinas Says Additional Cost Optimization Measures Expected To Realize Total Annual Savings Of More Than $100M Compared To FY24; Board Authorizes $100M Stock Repurchase
📈 PositiveBenzinga•Sep 17, 2025, 08:33 PM
Frequently Asked Questions about ARVN
What is ARVN's current stock price?
Arvinas, Inc. (ARVN) is currently trading at $11.68 per share. The stock has moved +3.55% today.
What is the analyst price target for ARVN?
The average analyst price target for ARVN is $13.50, based on 1 analyst.
What sector is Arvinas, Inc. in?
Arvinas, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ARVN's market cap?
Arvinas, Inc. has a market capitalization of $0.85 billion, making it a small-cap company.
Does ARVN pay dividends?
No, Arvinas, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATXS
Astria Therapeutics, Inc.
$12.83
Mkt Cap: $0.7B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
DAWN
Day One Biopharmaceuticals, Inc.
$9.24
Mkt Cap: $0.9B
DNA
Ginkgo Bioworks Holdings, Inc.
$8.10
Mkt Cap: $0.4B
ERAS
Erasca, Inc.
$3.45
Mkt Cap: $1.0B
GERN
Geron Corporation
$1.33
Mkt Cap: $0.8B
IOVA
Iovance Biotherapeutics, Inc.
$2.48
Mkt Cap: $0.8B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
REPL
Replimune Group, Inc.
$9.88
Mkt Cap: $0.8B
VALN
Valneva SE
$8.07
Mkt Cap: $0.7B
Explore stocks similar to ARVN for comparison